Celgene goes global with $2.9B Pharmion buyout

Celgene took a big stride toward its goal of becoming a global marketer of blood cancer therapies with the news over the weekend that it is buying Pharmion for $2.9 billion. That buyout amount is 11 times Pharmion's annual revenue and a 46 percent premium for its shares. Pharmion sells Vidaza and Thalomid and has extensive operations in Europe, where Celgene has been particularly interested in expanding. Celgene owns Thalomid and sells the multiple myeloma drug in the U.S. Celgene's lead therapy is Revlimid. The buyout also covers a late-stage therapy for small-cell lung cancer and the mid-stage oncology drug MGCD0103.

"The rationale for the deal is fairly clear," says Celgene CEO Sol Barer. "It's another important step as we evolve to become what we want to become: a global leader in hematology and cancer." Celgene is the seventh largest biotech by sales volume. The deal is expected to close next summer.


- see this release
- read the report on the buyout from TheStreet.com
- and here's the article from Forbes

Related Articles:
Array partners with Celgene, nets $40M upfront. Report
Celgene accelerates program on positive psoriasis data. Report
Pharmion nets cancer therapy in Cabrellis buyout. Report
Pharmion signs $270M licensing deal for GPC's satraplatin. Report

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.